Ann: SNT-5505 awarded US FDA Fast Track designation, page-10

  1. 3,140 Posts.
    lightbulb Created with Sketch. 1194
    Never a truer word stated:

    Gary Phillips, Chief Executive Officer of Syntara, stated: "To have the FDA recognise the quality of the pre-clinical and clinical results generated to date, as well as the therapeutic promise of SNT-5505 through this Fast Track designation, is an outstanding development for Syntara”

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
5.8¢
Change
0.000(0.00%)
Mkt cap ! $92.76M
Open High Low Value Volume
5.8¢ 5.9¢ 5.7¢ $64.55K 1.128M

Buyers (Bids)

No. Vol. Price($)
5 576750 5.6¢
 

Sellers (Offers)

Price($) Vol. No.
5.8¢ 9141 2
View Market Depth
Last trade - 12.59pm 07/08/2025 (20 minute delay) ?
SNT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.